EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Lipid Changes After Induction Therapy in Patients with Inflammatory Bowel Disease: Effect of Different Drug Classes and Inflammation

Jasmijn A M Sleutjes iD, Jeanine E Roeters van Lennep iD, C Janneke van der Woude, Annemarie C de Vries

Inflammatory Bowel Diseases · 03.04.2023 · 29 (4) · 531-538

DOI: 10.1093/ibd/izac100 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Inflammatory Bowel Diseases, online erschienen am 19.05.2022. Verfasst von Jasmijn A M Sleutjes und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, Erasmus Medical Center, Rotterdam, the Netherlands. Hauptthemen laut MEDLINE: Induction Chemotherapy, Inflammatory Bowel Diseases. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Dyslipidemia may be an important modifiable risk factor contributing to the increased cardiovascular risk in inflammatory bowel disease (IBD). The lipid metabolism is subject to both systemic inflammation and drug therapy; however, it is unclear if this effect is drug-class dependent. Our aim was to assess lipid changes after IBD induction therapy and evaluate associated factors with a particular focus on drug class and disease activity.

Methods

In this prospective study, consecutive IBD patients starting systemic therapy (eg, corticosteroids, thiopurines, methotrexate, anti-TNF-α agents, vedolizumab, ustekinumab, and tofacitinib) were included. Primary outcomes were changes in total cholesterol, high density lipoprotein cholesterol (HDL-c), low-density lipoprotein cholesterol (LDL-c), and triglycerides at week 10.

Results

One hundred ninety-eight IBD patients (107 women [54%], median age 36 years; interquartile range [IQR], 27-47) were included: 137 Crohn’s disease (67%), 61 ulcerative colitis (29%), and 8 IBD-unclassified (4%). Median C-reactive protein and fecal calprotectin at baseline were 5.1 mg/L (IQR, 1.6-12.0) and 1040 ug/g (IQR, 383-1800), respectively. Relative increases in total cholesterol, HDL-c, and LDL-c were significant after prednisone (+26%, +31%, +12%) and tofacitinib therapy (+20%, +25%, +26%), respectively. Results remained after adjusting for concomitant corticosteroids, cholestyramine, and PSC diagnosis. Changes in clinical scores were inversely correlated with total cholesterol changes (R −186, P = .014), as was CRP with total cholesterol and LDL-c (R −0.292 and R −0.259, P < .001). No correlation was found with FCP. Lipid changes remained after adjusting for age and CRP.

Conclusions

Prednisone and tofacitinib induction therapy significantly increase serum lipid levels, whereas no changes were observed in other drug classes. The observations seem drug-specific inasmuch as adjustment for systemic inflammation did not alter the results.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Induction ChemotherapyInflammatory Bowel DiseasesHumansFemaleAdultCholesterol, LDLPrednisoneProspective StudiesTumor Necrosis Factor InhibitorsInflammationCholesterol, HDL

Stichwörter der Autor:innen

biologicscorticosteroidsimmunomodulatorslipidstofacitinib

Substanzen

Cholesterol, LDLPrednisoneTumor Necrosis Factor InhibitorsCholesterol, HDL

Autor:innen und Institutionen

  • Department of Gastroenterology and Hepatology, Erasmus Medical Center, Rotterdam, the Netherlands.
  • Department of Internal Medicine, Erasmus Medical Center, Rotterdam, the Netherlands.

ORCID-Profile: Jasmijn A M Sleutjes, Jeanine E Roeters van Lennep

Zitieren

APA

Sleutjes, J. A. M., Roeters van Lennep, J. E., van der Woude, C. J., & de Vries, A. C. (2023). Lipid Changes After Induction Therapy in Patients with Inflammatory Bowel Disease: Effect of Different Drug Classes and Inflammation. Inflammatory Bowel Diseases, 29(4), 531-538. https://doi.org/10.1093/ibd/izac100

Vancouver

Sleutjes JAM, Roeters van Lennep JE, van der Woude CJ, de Vries AC. Lipid Changes After Induction Therapy in Patients with Inflammatory Bowel Disease: Effect of Different Drug Classes and Inflammation. Inflammatory Bowel Diseases. 2023;29(4):531-538. doi:10.1093/ibd/izac100

BibTeX
@article{Sleutjes2023,
  author = {Sleutjes, Jasmijn A M and Roeters van Lennep, Jeanine E and van der Woude, C Janneke and de Vries, Annemarie C},
  title = {Lipid Changes After Induction Therapy in Patients with Inflammatory Bowel Disease: Effect of Different Drug Classes and Inflammation},
  journal = {Inflammatory Bowel Diseases},
  year = {2023},
  volume = {29},
  number = {4},
  pages = {531--538},
  doi = {10.1093/ibd/izac100}
}
Kostenlos starten →